14/11/2002
ReGen Therapeutics Plc (‘the Company’), a company developing ColostrininTM as a potential therapy for Alzheimer’s disease, announces that it has today sent to shareholders a circular containing a notice convening an extraordinary general meeting of the Company (the ‘Circular’) for 2.00 p.m. on 10 December 2002 (‘EGM’).
Following the issue on 25 September 2002 of 21,212,121 new ordinary shares of the Company in consideration for shares in New Opportunities Investment Trust PLC, an investment trust which invests primarily in the quoted equity and debt securities of selected smaller companies, the Directors of the Company are seeking at the EGM renewal of their authorities to issue shares and/or other securities so as to provide them with flexibility in the future for possible fundraisings and other share issuances.
Other than in respect of the grant of options pursuant to the Company’s share option schemes, the Directors of the Company have no present intention of using the authorities granted to them at the EGM, assuming the resolutions are passed.
Copies of the Circular will be available, for collection only, free of charge to the public, from the Company, Suite 406, Langham House, 29-30 Margaret Street, London W1W 8SA during normal office hours on any day (Saturdays, Sundays excepted) from today until 14 December 2002.
For further information, please contact:
Andrew Marshall
Marshall Robinson Roe
Tel No 020 7489 2033